SMHC-DIA CNS Innovation Forum & CCTN-P 2026 Annual Meeting
CNS research is advancing rapidly, but high development failure rates highlight the need to focus on the clinical insights that matter most. Join the 2026 SMHC-DIA CNS Innovation Forum as we explore how simplifying complex data—and leveraging AI—can help reveal clearer clinical value.
Clario is presenting and exhibiting, and we’d love to meet up! Stop by our booth to learn how we can provide the expertise and tools needed to achieve your respiratory research goals efficiently and effectively.
Session information:
Date: August 22, 2026
Time: Afternoon
Abstract title: The biomarker era: precision medicine for neuroscience clinical trials
Neuroscience studies are challenging because disease progression is highly variable. Precision medicine starts with identifying the right patients earlier and more accurately. The emergence of MRI and PET biomarkers for complex brain diseases signifies a new era in CNS drug development. This presentation will explore how neuroimaging can support patient stratification, early detection, and endpoint development for clinical trials.
Speaker
David Scott, Ph.D.
VP, Medical and Scientific Affairs at Clario
David Scott is Vice President, Medical and Scientific Affairs at Clario. His aim is to facilitate drug development through standardized measurement of the neural correlates of neurodegenerative and other centrally mediated diseases. As a student at Johns Hopkins University and the University of Michigan, he employed multi-modal imaging approaches including dynamic PET and functional MRI to study the neurobiology of placebo analgesia. At Omneuron, he developed real-time fMRI applications aimed at treating chronic pain, depression and addiction. Since joining Clario in 2012, David’s focus has been to enable MRI and molecular imaging solutions toward safety, eligibility, and therapeutic efficacy endpoints. He works with radiologists, physicists, software engineers, and operational specialists on the design, execution, analysis, and interpretation of neuroscience clinical trial imaging data. His motivation is to enable neuroimaging to accelerate the delivery of therapeutic benefit to patients around the world.